1 はじめに
1.1 調査目的 42
1.2 市場の定義 43
1.2.1 包含と除外 43
1.3 市場範囲 44
1.3.1 対象市場 44
1.4 考慮した年数 45
1.5 考慮した通貨 46
1.6 利害関係者 46
1.7 変化の概要 46
1.8 AI／ジェネレーティブAIの影響 47
2 調査方法 48
2.1 調査データ 48
2.1.1 二次データ 49
2.1.2 一次データ 49
2.2 市場推計方法 51
2.2.1 市場規模の推定 51
2.2.2 トップダウンアプローチ 54
2.3 市場成長率の予測 55
2.4 市場の内訳とデータの三角測量 57
2.5 リサーチの前提 58
2.6 調査の限界 58
2.7 リスク分析 59
3 エグゼクティブサマリー 60
4 プレミアムインサイト 66
4.1 ゲノミクス市場の概要
4.2 アジア太平洋地域：ゲノミクス市場：オファリング別 67
4.3 ゲノミクス市場：地理的成長機会 68
4.4 ゲノミクス市場シェア：製品エンドユーザー別（2023年） 69
5 市場の概要 70
5.1 はじめに 70
5.2 市場ダイナミクス 70
5.2.1 推進要因 71
5.2.1.1 ゲノミクス・プロジェクトに対する政府資金の増加 71
5.2.1.2 ウイルス性疾患および遺伝性疾患の有病率の増加 72
5.2.1.3 NGSプラットフォームの進歩 73
5.2.1.4 ゲノミクスの用途の拡大 74
5.2.2 阻害要因 74
5.2.2.1 高い投資コスト 74
5.2.3 機会 75
5.2.3.1 精密医療におけるゲノミクスの利用の増加 75
5.2.3.2 ゲノミクスの技術的進歩 75
5.2.4 課題 76
5.2.4.1 大量のデータセットの取り扱いとその解析 76
5.2.4.2 ゲノミクスの臨床的有用性 76
5.3 顧客のビジネスに影響を与えるトレンド／混乱 77
5.4 規制の状況 77
5.4.1 規制のシナリオ
5.4.2 規制機関、政府機関、その他の組織 79
5.5 バリューチェーン分析 82
5.6 技術分析 84
5.6.1 主要技術 85
5.6.1.1 合成によるシーケンス 85
5.6.1.2 1分子リアルタイムシーケンス 85
5.6.1.3 ナノポアシーケンス 86
5.6.1.4 qPCR 86
5.6.1.5 dPCR 86
5.6.1.6 マイクロアレイ技術 87
5.6.2 相補的技術 87
5.6.2.1 細胞遺伝学 87
5.6.2.2 合成生物学 87
5.6.2.3 マルチオミクス 88
5.6.2.4 シングルセル解析 88
5.6.3 隣接技術 89
5.6.3.1 サンプル前処理技術 89
5.6.3.2 データ解析 89
5.6.3.3 バイオインフォマティクスと計算生物学 89
5.6.3.4 人工知能と機械学習 90
5.7 価格分析 90
5.7.1 主要企業の平均販売価格（製品別） 91
5.7.1.1 主要企業の平均販売価格（機器別） 91
5.7.1.2 主要企業の平均販売価格（消耗品別） 92
5.7.1.3 主要企業の平均販売価格（サービス別） 94
5.7.2 平均販売価格（地域別） 95
5.8 特許分析 96
5.9 サプライチェーン分析 98
5.10 エコシステム分析 100
5.11 主要な会議とイベント（2024-2025年） 101
5.12 ポーターの5つの力分析 102
5.12.1 ポーターの5つの力分析 102
5.12.2 競合ライバルの激しさ 103
5.12.3 サプライヤーの交渉力 103
5.12.4 買い手の交渉力 103
5.12.5 代替品の脅威 103
5.12.6 新規参入企業の脅威 104
5.13 主要ステークホルダーと購買基準 104
5.13.1 購入プロセスにおける主要ステークホルダー 104
5.13.2 主要な購買基準（エンドユーザー別） 105
5.14 投資と資金調達のシナリオ 106
5.15 ケーススタディ分析 108
5.16 貿易分析 109
5.16.1 フローサイトメーター（HSコード902780）の輸入額（2017～2021年） 112
5.16.2 フローサイトメーター（HSコード902780）の輸出額、2017～2021年 113
5.16.3 フローサイトメーター（HSコード 902780）の輸入データ（2022-2023年） 114
5.16.4 フローサイトメーター（HSコード902780）の輸出データ、2022-2023 116
5.17 AIがゲノミクス市場に与える影響 117
6 ゲノミクス市場：オファリング別 119
6.1 導入 120
6.2 製品 120
6.3 サービス 123
7 ゲノミクス市場：製品タイプ別 127
7.1 導入 128
7.2 試薬、キット、消耗品 128
7.2.1 消耗品分野で事業展開する多数のプレーヤーが消耗品、キット、試薬の需要を促進 128
7.3 計器 133
7.3.1 市場成長を支える技術的進歩 133
7.4 バイオインフォマティクスツール 137
7.4.1 生データを意味のある洞察に変えるバイオインフォマティクスツール 137
8 ゲノミクス製品市場、技術別 141
8.1 導入 142
8.2 シークエンシング 142
8.2.1 シークエンシング中のDNA修飾の直接検出が市場成長を促進 142
8.3 PCR 146
8.3.1 バイオマーカー探索の需要増加が市場成長を促進 146
8.4 遺伝子編集 150
8.4.1 新しい治療アプローチへの需要の高まりが成長を促進 150
8.5 フローサイトメトリー 153
8.5.1 アグリゲノミクスにおけるフローサイトメトリー需要の高まりが市場成長を促進 153
8.6 マイクロアレイ 157
8.6.1 ハイスループット技術の採用増加が市場成長を制限 157
8.7 in situハイブリダイゼーション 160
8.7.1 高精度遺伝子発現解析への需要の高まりが同分野の成長を促進 160
8.8 その他の技術 164
9 ゲノミクス製品市場、エンドユーザー別 168
9.1 導入 169
9.2 病院、診断研究所、診療所 169
9.2.1 疾患診断・治療への応用拡大が市場成長を牽引 169
9.3 学術・研究機関 174
9.3.1 研究機関のゲノミクス研究における研究意欲の高まりが市場成長を支える 174
9.4 製薬・バイオテクノロジー企業 177
9.4.1 臨床ゲノミクスにおける包括的ゲノムデータへの需要の高まりが成長を促進 177
9.5 CROS 181
9.5.1 製薬企業とCROSの協力関係の高まりが市場成長を促進 181
9.6 その他のエンドユーザー 184
10 ゲノミクス市場：サービスタイプ別 188
10.1 導入 189
10.2 ゲノムプロファイリング・シークエンシングサービス 189
10.2.1 市場の成長を支える臨床採用におけるシーケンス技術の採用増加 189
10.3 サンプル調製およびライブラリー調製サービス 193
10.3.1 がんおよび希少疾患診断の需要増加が市場成長を促進 193
10.4 バイオインフォマティクスサービス 196
10.4.1 先進的個別化医療への需要の高まりが市場成長を後押し 196
11 ゲノミクス市場：用途別 200
11.1 導入 201
11.2 創薬と医薬品開発 201
11.2.1 創薬・医薬品開発がゲノミクス市場最大のアプリケーションに 201
11.3 診断薬 205
11.3.1 臨床ゲノミクスによる需要の増加が市場成長を支える 205
11.3.1.1 がん領域 208
11.3.1.1.1 標的療法の需要増加が市場成長を牽引 208
11.3.2 感染症 213
11.3.2.1 クリニカルゲノミクスにおける包括的ゲノムデータへの需要の高まりが市場成長を促進 213
11.3.3 リプロダクティブ・ヘルス 216
11.3.3.1 遺伝性疾患への注目の高まりが市場成長を牽引 216
11.3.4 その他の診断アプリケーション 219
11.3.4.1 臨床ゲノミクスにおける包括的ゲノムデータへの需要の高まりが市場成長を促進 219
11.3.5 農業・動物研究 223
11.3.5.1 作物の生産性向上に役立つゲノミクス 223
11.4 その他の用途 226
12 ゲノミクス市場：研究タイプ別 230
12.1 はじめに 231
12.2 機能ゲノミクス 231
12.2.1 機能的ゲノム研究への注力の高まりが市場成長を牽引 231
12.3 バイオマーカー探索 235
12.3.1 精密医療への需要の高まりが市場成長を支える 235
12.4 パスウェイ解析 238
12.4.1 複雑な疾患の有病率の上昇が市場成長を促進 238
12.5 エピゲノミクス 242
12.5.1 エピジェネティクス研究への投資の増加が市場成長を後押し 242
12.6 その他の研究タイプ 245
13 ゲノミクスサービス市場：エンドユーザー別 249
13.1 導入 250
13.2 病院、診断研究所、クリニック 250
13.2.1 疾患診断と治療における応用の増加が市場成長を牽引 250
13.3 学術・研究機関 254
13.3.1 研究機関のゲノミクス研究に対する研究意欲の高まりが市場成長を支える 254
13.4 製薬・バイオテクノロジー企業 257
13.4.1 臨床ゲノミクスにおける包括的ゲノムデータへの需要の高まりが成長を促進 257
13.5 その他のエンドユーザー 261
14 ゲノミクス市場：地域別 265
14.1 はじめに 266
14.2 北米 267
14.2.1 北米：マクロ経済見通し 272
14.2.2 米国 273
14.2.2.1 北米では米国が市場を支配する見込み 273
14.2.3 カナダ 277
14.2.3.1 ゲノミクス研究における政府のイニシアチブの増加が市場成長を後押し 277
14.3 欧州 282
14.3.1 欧州： マクロ経済見通し 287
14.3.2 ドイツ 288
14.3.2.1 ドイツが欧州ゲノム市場を支配 288
14.3.3 イギリス 292
14.3.3.1 市場成長を支えるゲノム研究への戦略的イニシアティブと資金提供 292
14.3.4 フランス 296
14.3.4.1 ゲノミクス研究に対する政府投資の増加が成長を牽引 296
14.3.5 イタリア 300
14.3.5.1 良好な資金調達シナリオが高度なシーケンス技術の採用を促進 300
14.3.6 スペイン 304
14.3.6.1 個別化医療の進展への注目の高まりが市場成長を後押し 304
14.3.7 その他の欧州 308
14.4 アジア太平洋地域 313
14.4.1 アジア太平洋地域：マクロ経済見通し 318
14.4.2 中国 319
14.4.2.1 予測期間中、中国がアジア太平洋市場を支配 319
14.4.3 日本 323
14.4.3.1 ゲノミクスにおける共同研究の増加が市場を牽引 323
14.4.4 インド 327
14.4.4.1 ゲノミクスに対する政府・民間の取り組みが市場を促進 327
14.4.5 オーストラリア 331
14.4.5.1 オーストラリアにおけるゲノム研究の増加が市場成長を支える 331
14.4.6 韓国 335
14.4.6.1 韓国では高度なシーケンス技術への需要が市場成長を支える 335
14.4.7 その他のアジア太平洋地域 339
14.5 ラテンアメリカ 345
14.5.1 ラテンアメリカ：マクロ経済見通し 349
14.5.2 ブラジル 350
14.5.2.1 ゲノミクスの進歩に対する政府投資の増加がブラジル市場を牽引 350
14.5.3 メキシコ 354
14.5.3.1 慢性疾患治療需要の増加がメキシコ市場の成長を支える 354
14.5.4 その他のラテンアメリカ 358
14.6 中東 363
14.6.1 中東 マクロ経済見通し 366
14.6.2 GCC諸国 367
14.6.2.1 サウジアラビア 371
14.6.2.1.1 サウジアラビアの医療費増加が市場成長を後押し 371
14.6.2.2 アラブ首長国連邦 376
14.6.2.2.1 アラブ首長国連邦ではゲノムシーケンスの進展に向けた共同研究が活発化し、市場成長を後押し 376
14.6.2.3 その他のGCC諸国 380
14.6.3 その他の中東地域 385
14.7 アフリカ 389
14.7.1 精密医療への関心の高まりがアフリカ市場を牽引 389
14.7.2 アフリカ：マクロ経済見通し 393
15 競争環境 395
15.1 はじめに 395
15.2 主要企業が採用した戦略／勝利への権利 395
15.3 収益分析 397
15.4 市場シェア分析 398
15.5 ブランド／製品比較分析 400
15.5.1 イルミナ社 401
15.5.2 サーモフィッシャーサイエンティフィック 401
15.5.3 ダナハーコーポレーション 401
15.5.4 ロシュ 401
15.5.5 キアゲン 401
15.6 企業評価マトリックス：主要企業（2023年） 401
15.6.1 スター企業 402
15.6.2 新興リーダー 402
15.6.3 浸透型プレーヤー 402
15.6.4 参加企業 402
15.6.5 企業フットプリント：主要プレーヤー（2023年） 404
15.7 企業評価マトリクス：新興企業／SM（2023年） 409
15.7.1 先進的企業 409
15.7.2 対応力のある企業 409
15.7.3 ダイナミックな企業 409
15.7.4 スタートアップ企業 409
15.7.5 競争ベンチマーキング 411
15.8 ゲノミクスベンダーの評価と財務指標 412
15.9 競争シナリオ 413
15.9.1 取引 413
15.9.2 拡張 414
16 企業プロファイル 415
Illumina Inc. (US)
Thermo Fisher Scientific Inc. (US)
F. Hoffmann-LA Roche Ltd. (Switzerland)
Danaher Corporation (US)
QIAGEN (Germany)
Agilent Technologies Inc. (US)
Revvity (US)
Laboratory Corporation of America Holdings (US)
IQVIA Inc. (US)
Charles River Laboratories (US)
Bio-Rad Laboratories Inc. (US)
Eurofins Scientific (Luxembourg)
PacBio (US)
Oxford Nanopore Technologies plc. (UK)
Takara Bio Inc. (Japan)
BGI Group (China)
Eppendorf SE (Germany)
Merck KGaA (Germany)
BD (US)
Abbott (US)
10X Genomics (US)
New England Biolabs (US)
Promega Corporation (US)
Creative Biogene (US)
Novogene Co.Ltd. (China)
Helix Inc. (US)
Phalanx Biotech Group (US)
Polaris Genomics (US)
17 付録 553
17.1 ディスカッションガイド 553
17.2 Knowledgestore： Marketsandmarketsの購読ポータル 558
17.3 カスタマイズオプション 560
17.4 関連レポート 561
17.5 著者の詳細 562
Growth in the genomics market is mainly driven by factors like expanding genomic studies to include the human microbiome, increasing focus on genomics initiatives in low- and middle-income countries, and increased adoption of personalized medicines. However, the initial cost concern to set up the equipment is impacting the growth of the genomics market.
“The reagents, kits, and consumables segment accounted for the largest share by products segment in the genomics market in 2023”
The genomics market is segmented into reagents, kits, and consumables, instruments, and bioinformatics tools in 2023. The reagents, kits, and consumables is the segment with the largest share in products. The reagents, kits, and consumables segment dominates the product type category of the genomics market. They are crucial for almost all genomic workflows, starting from DNA/RNA extraction, amplification, and sequencing up to analysis, and therefore, are needed for nearly all processes involved in either research or clinical applications. Demand is thus triggered by the ever-growing number of genomic experiments conducted in diagnostics, personalized medicine, and drug development. Every one of these workflows demands a constant replenishment of high-quality reagents and kits to make genomic data generation accurate and reliable. Also, the rapid adoption of state-of-the-art technologies such as NGS and PCR accelerates the demand for application-specific reagents and consumables. The steady growth experienced in genomics areas such as healthcare, research, and biotechnology further builds upon the revenue volume realized on the consumable end and maintains its market top-line position.
“The academic & research institutes segment accounted for the largest share by products end-user segment in the genomics market in 2023”
The genomics product market is segmented into hospitals, clinics & diagnostics laboratories, academic & research institutes, pharmaceutical & biotechnologies companies, CROs, and other end users. The hospitals, clinics & diagnostics laboratories are the segment with the largest share in the end-user segment in 2023. The large share of hospitals, clinics & diagnostics laboratories is due to the increased patient engagement in genomic research through citizen science initiatives to democratize data collection and accelerate the discoveries in rare diseases and personalized medicine. However, the pharmaceutical & biotechnological companies accounted for the second largest share in the segment.
“The Asia Pacific region is growing at the highest CAGR in the genomics market from 2024 to 2029.”
The Asia Pacific is estimated to be the fastest-growing segment of the market owing to the large scale of population genomics projects, and the rising demand for precision medicines is supporting the growth. Further, the rising prevalence of rare and genetic diseases is attributed to the aging population of countries such as Japan, and China. This is supporting the adoption of genomics technologies in healthcare management and treatment driving the market growth.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45% CXOs and Director-level - 30%, and Executives - 25%,
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, and Middle East -5%.
List of Companies Profiled in the Report:
• Illumina, Inc. (US)
• Thermo Fisher Scientific Inc. (US)
• F. Hoffmann-LA Roche Ltd. (Switzerland)
• Danaher Corporation (US)
• QIAGEN (Germany)
• Agilent Technologies, Inc. (US)
• Revvity (US)
• Laboratory Corporation of America Holdings (US)
• IQVIA Inc. (US)
• Charles River Laboratories (US)
• Bio-Rad Laboratories, Inc. (US)
• Eurofins Scientific (Luxembourg)
• PacBio (US)
• Oxford Nanopore Technologies plc. (UK)
• Takara Bio Inc. (Japan)
• BGI Group (China)
• Eppendorf SE (Germany)
• Merck KGaA (Germany)
• BD (US)
• Abbott (US)
• 10X Genomics (US)
• New England Biolabs (US)
• Promega Corporation (US)
• Creative Biogene (US)
• Novogene Co., Ltd. (China)
• Helix, Inc. (US)
• Phalanx Biotech Group (US)
• Polaris Genomics (US)
Research Coverage:
This research report categorizes the genomics market by offerings (products and services), products by type (reagents, kits and consumables, instruments, bioinformatics tools), products by technology (sequencing, PCR, gene editing, flow cytometry, microarrays, in situ hybridization, and other technologies), products by end user (hospitals, diagnostic laboratories, and clinics, academic and research institutes, pharmaceutical and biotechnology companies, CROs, and other end users), services by type (genomics profiling and sequencing services, sample preparation and library preparation service, bioinformatics service), application (drug discovery & development, diagnostics, agriculture and animal research, and other applications), diagnostic applications (oncology, infectious disease, reproductive health, and other diagnostic applications), study type (functional genomics, biomarker discovery, pathway analysis, epigenomics, and other study types) end user by services (hospitals and clinics, academic & research institutes, pharmaceutical & biotechnology companies and other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the genomics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product & service portfolio, key strategies such as product & service launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the genomics market. Competitive analysis of top players and upcoming startups in the genomics market ecosystem is covered in this report
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall genomics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (Increasing government funding for genomics projects, Increasing prevalence of viral and inherited disorders, Advancement in NGS platforms, Growing applications of genomics), restraints (High investment costs), opportunities (Increasing use of genomics in precision medicine, Technological advancements in genomics), and challenges (Handling of large volume of data sets and their analysis, Clinical utility of genomics) influencing the growth of the market.
•Product Development/Innovation: Detailed insights on newly launched products/services of the genomics market
•Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
•Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the genomics market
•Competitive Assessment: Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-LA Roche Ltd. (Switzerland), Danaher Corporation (US), QIAGEN (Germany), Agilent Technologies, Inc. (US), Revvity (US), Laboratory Corporation of America Holdings (US), IQVIA Inc. (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), PacBio (US), Oxford Nanopore Technologies plc. (UK), Takara Bio Inc. (Japan), BGI Group (China), Eppendorf SE (Germany), Merck KGaA (Germany), BD (US), Abbott (US), 10X Genomics (US), New England Biolabs (US), Promega Corporation (US), Creative Biogene (US), Novogene Co., Ltd. (China), Helix, Inc. (US), Phalanx Biotech Group (US), Polaris Genomics (US) and among others in the market.
1 INTRODUCTION 42
1.1 STUDY OBJECTIVES 42
1.2 MARKET DEFINITION 43
1.2.1 INCLUSIONS AND EXCLUSIONS 43
1.3 MARKET SCOPE 44
1.3.1 MARKETS COVERED 44
1.4 YEARS CONSIDERED 45
1.5 CURRENCY CONSIDERED 46
1.6 STAKEHOLDERS 46
1.7 SUMMARY OF CHANGES 46
1.8 IMPACT OF AI/GENERATIVE AI 47
2 RESEARCH METHODOLOGY 48
2.1 RESEARCH DATA 48
2.1.1 SECONDARY DATA 49
2.1.2 PRIMARY DATA 49
2.2 MARKET ESTIMATION METHODOLOGY 51
2.2.1 MARKET SIZE ESTIMATION 51
2.2.2 TOP-DOWN APPROACH 54
2.3 MARKET GROWTH RATE PROJECTIONS 55
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 57
2.5 RESEARCH ASSUMPTIONS 58
2.6 RESEARCH LIMITATIONS 58
2.7 RISK ANALYSIS 59
3 EXECUTIVE SUMMARY 60
4 PREMIUM INSIGHTS 66
4.1 GENOMICS MARKET OVERVIEW 66
4.2 ASIA PACIFIC: GENOMICS MARKET, BY OFFERING 67
4.3 GENOMICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 68
4.4 GENOMICS MARKET SHARE, BY PRODUCT END USER, 2023 69
5 MARKET OVERVIEW 70
5.1 INTRODUCTION 70
5.2 MARKET DYNAMICS 70
5.2.1 DRIVERS 71
5.2.1.1 Increasing government funding for genomics projects 71
5.2.1.2 Increasing prevalence of viral and inherited disorders 72
5.2.1.3 Advancements in NGS platforms 73
5.2.1.4 Growing applications of genomics 74
5.2.2 RESTRAINTS 74
5.2.2.1 High investment costs 74
5.2.3 OPPORTUNITIES 75
5.2.3.1 Increasing use of genomics in precision medicine 75
5.2.3.2 Technological advancements in genomics 75
5.2.4 CHALLENGES 76
5.2.4.1 Handling of large volumes of data sets and their analysis 76
5.2.4.2 Clinical utility of genomics 76
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77
5.4 REGULATORY LANDSCAPE 77
5.4.1 REGULATORY SCENARIO 77
5.4.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
5.5 VALUE CHAIN ANALYSIS 82
5.6 TECHNOLOGICAL ANALYSIS 84
5.6.1 KEY TECHNOLOGIES 85
5.6.1.1 Sequencing by synthesis 85
5.6.1.2 Single-molecule real-time sequencing 85
5.6.1.3 Nanopore sequencing 86
5.6.1.4 qPCR 86
5.6.1.5 dPCR 86
5.6.1.6 Microarray technology 87
5.6.2 COMPLEMENTARY TECHNOLOGIES 87
5.6.2.1 Cytogenetics 87
5.6.2.2 Synthetic biology 87
5.6.2.3 Multiomics 88
5.6.2.4 Single-cell analysis 88
5.6.3 ADJACENT TECHNOLOGIES 89
5.6.3.1 Sample preparation technologies 89
5.6.3.2 Data analysis 89
5.6.3.3 Bioinformatics and computational biology 89
5.6.3.4 Artificial intelligence and machine learning 90
5.7 PRICING ANALYSIS 90
5.7.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY OFFERING 91
5.7.1.1 Average selling price of key players, by instrument 91
5.7.1.2 Average selling price of key players, by consumable 92
5.7.1.3 Average selling price of key players, by service 94
5.7.2 AVERAGE SELLING PRICE, BY REGION 95
5.8 PATENT ANALYSIS 96
5.9 SUPPLY CHAIN ANALYSIS 98
5.10 ECOSYSTEM ANALYSIS 100
5.11 KEY CONFERENCES AND EVENTS, 2024–2025 101
5.12 PORTER’S FIVE FORCES ANALYSIS 102
5.12.1 PORTER’S FIVE FORCES ANALYSIS 102
5.12.2 INTENSITY OF COMPETITIVE RIVALRY 103
5.12.3 BARGAINING POWER OF SUPPLIERS 103
5.12.4 BARGAINING POWER OF BUYERS 103
5.12.5 THREAT OF SUBSTITUTES 103
5.12.6 THREAT OF NEW ENTRANTS 104
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 104
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 104
5.13.2 KEY BUYING CRITERIA, BY END USER 105
5.14 INVESTMENT AND FUNDING SCENARIO 106
5.15 CASE STUDY ANALYSIS 108
5.16 TRADE ANALYSIS 109
5.16.1 IMPORT VALUE FOR FLOW CYTOMETERS (HS CODE 902780), 2017–2021 112
5.16.2 EXPORT VALUE FOR FLOW CYTOMETERS (HS CODE 902780), 2017–2021 113
5.16.3 IMPORT DATA FOR FLOW CYTOMETERS (HS CODE 902780), 2022–2023 114
5.16.4 EXPORT DATA FOR FLOW CYTOMETERS (HS CODE 902780), 2022–2023 116
5.17 IMPACT OF AI ON GENOMICS MARKET 117
6 GENOMICS MARKET, BY OFFERING 119
6.1 INTRODUCTION 120
6.2 PRODUCTS 120
6.3 SERVICES 123
7 GENOMICS MARKET, BY PRODUCT TYPE 127
7.1 INTRODUCTION 128
7.2 REAGENTS, KITS, AND CONSUMABLES 128
7.2.1 LARGE NUMBER OF PLAYERS OPERATING IN CONSUMABLES SPACE PROPEL DEMAND FOR CONSUMABLES, KITS, AND REAGENTS 128
7.3 INSTRUMENTS 133
7.3.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT MARKET GROWTH 133
7.4 BIOINFORMATICS TOOLS 137
7.4.1 BIOINFORMATICS TOOLS TO HELP TURN RAW DATA INTO MEANINGFUL INSIGHTS 137
8 GENOMICS PRODUCTS MARKET, BY TECHNOLOGY 141
8.1 INTRODUCTION 142
8.2 SEQUENCING 142
8.2.1 DIRECT DETECTION OF DNA MODIFICATIONS DURING SEQUENCING TO DRIVE MARKET GROWTH 142
8.3 PCR 146
8.3.1 RISING DEMAND FOR BIOMARKER DISCOVERY TO PROPEL MARKET GROWTH 146
8.4 GENE EDITING 150
8.4.1 RISING DEMAND FOR NEWER THERAPEUTIC APPROACH DRIVING GROWTH 150
8.5 FLOW CYTOMETRY 153
8.5.1 RISING DEMAND FOR FLOW CYTOMETRY FOR AGRIGENOMICS TO DRIVE MARKET GROWTH 153
8.6 MICROARRAYS 157
8.6.1 RISING ADOPTION OF HIGH THROUGHPUT TECHNOLOGIES LIMITING MARKET GROWTH 157
8.7 IN SITU HYBRIDIZATION 160
8.7.1 INCREASING DEMAND FOR PRECISE GENE EXPRESSION ANALYSIS DRIVING GROWTH OF SEGMENT 160
8.8 OTHER TECHNOLOGIES 164
9 GENOMICS PRODUCTS MARKET, BY END USER 168
9.1 INTRODUCTION 169
9.2 HOSPITALS, DIAGNOSTIC LABORATORIES, AND CLINICS 169
9.2.1 INCREASED APPLICATION IN DISEASE DIAGNOSTICS AND TREATMENT DRIVING MARKET GROWTH 169
9.3 ACADEMIC AND RESEARCH INSTITUTES 174
9.3.1 RISING RESEARCH INTENSITY FOR GENOMICS RESEARCH AMONG INSTITUTES TO SUPPORT MARKET GROWTH 174
9.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 177
9.4.1 RISING DEMAND FOR COMPREHENSIVE GENOMIC DATA IN CLINICAL GENOMICS IS DRIVING GROWTH 177
9.5 CROS 181
9.5.1 RISING COLLABORATION BETWEEN PHARMA COMPANIES AND CROS DRIVING MARKET GROWTH 181
9.6 OTHER END USERS 184
10 GENOMICS MARKET, BY SERVICE TYPE 188
10.1 INTRODUCTION 189
10.2 GENOMIC PROFILING AND SEQUENCING SERVICES 189
10.2.1 INCREASED ADOPTION OF SEQUENCING TECHNOLOGIES IN CLINICAL ADOPTION TO SUPPORT MARKET GROWTH 189
10.3 SAMPLE PREPARATION AND LIBRARY PREPARATION SERVICES 193
10.3.1 INCREASED DEMAND FOR ONCOLOGY AND RARE DISEASE DIAGNOSTICS TO DRIVE MARKET GROWTH 193
10.4 BIOINFORMATICS SERVICES 196
10.4.1 RISING DEMAND FOR ADVANCED PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH 196
11 GENOMICS MARKET, BY APPLICATION 200
11.1 INTRODUCTION 201
11.2 DRUG DISCOVERY AND DEVELOPMENT 201
11.2.1 DRUG DISCOVERY AND DEVELOPMENT TO BE LARGEST APPLICATION IN GENOMICS MARKET 201
11.3 DIAGNOSTICS 205
11.3.1 RISING DEMAND DUE TO CLINICAL GENOMICS TO SUPPORT MARKET GROWTH 205
11.3.1.1 Oncology 208
11.3.1.1.1 Rising demand for targeted therapies to drive market growth 208
11.3.2 INFECTIOUS DISEASES 213
11.3.2.1 Rising demand for comprehensive genomic data in clinical genomics to drive market growth 213
11.3.3 REPRODUCTIVE HEALTH 216
11.3.3.1 Rising focus on genetic diseases to drive market growth 216
11.3.4 OTHER DIAGNOSTIC APPLICATIONS 219
11.3.4.1 Rising demand for comprehensive genomic data in clinical genomics to drive market growth 219
11.3.5 AGRICULTURE AND ANIMAL RESEARCH 223
11.3.5.1 Genomics to help improve crop productivity 223
11.4 OTHER APPLICATIONS 226
12 GENOMICS MARKET, BY STUDY TYPE 230
12.1 INTRODUCTION 231
12.2 FUNCTIONAL GENOMICS 231
12.2.1 INCREASED FOCUS ON FUNCTIONAL GENOME STUDIES TO DRIVE MARKET GROWTH 231
12.3 BIOMARKER DISCOVERY 235
12.3.1 RISING DEMAND FOR PRECISION MEDICINE TO SUPPORT MARKET GROWTH 235
12.4 PATHWAY ANALYSIS 238
12.4.1 RISING PREVALENCE OF COMPLEX DISEASES TO AUGMENT MARKET GROWTH 238
12.5 EPIGENOMICS 242
12.5.1 RISING INVESTMENTS FOR EPIGENETICS RESEARCH TO BOOST MARKET GROWTH 242
12.6 OTHER STUDY TYPES 245
13 GENOMICS SERVICES MARKET, BY END USER 249
13.1 INTRODUCTION 250
13.2 HOSPITALS, DIAGNOSTIC LABORATORIES, AND CLINICS 250
13.2.1 INCREASED APPLICATION IN DISEASE DIAGNOSTICS AND TREATMENT DRIVING MARKET GROWTH 250
13.3 ACADEMIC AND RESEARCH INSTITUTES 254
13.3.1 RISING RESEARCH INTENSITY FOR GENOMICS RESEARCH AMONG INSTITUTES TO SUPPORT MARKET GROWTH 254
13.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 257
13.4.1 RISING DEMAND FOR COMPREHENSIVE GENOMIC DATA IN CLINICAL GENOMICS TO DRIVE GROWTH 257
13.5 OTHER END USERS 261
14 GENOMICS MARKET, BY REGION 265
14.1 INTRODUCTION 266
14.2 NORTH AMERICA 267
14.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 272
14.2.2 US 273
14.2.2.1 US expected to dominate market in North America 273
14.2.3 CANADA 277
14.2.3.1 Increasing government initiatives in genomics research to boost market growth 277
14.3 EUROPE 282
14.3.1 EUROPE: MACROECONOMIC OUTLOOK 287
14.3.2 GERMANY 288
14.3.2.1 Germany to dominate European genomics market 288
14.3.3 UK 292
14.3.3.1 Strategic initiatives and funding for genomics research to support market growth 292
14.3.4 FRANCE 296
14.3.4.1 Increasing government investment in genomics research to drive growth 296
14.3.5 ITALY 300
14.3.5.1 Favorable funding scenario to drive adoption of advanced sequencing technology 300
14.3.6 SPAIN 304
14.3.6.1 Growing focus on advancements in personalized medicine to support market growth 304
14.3.7 REST OF EUROPE 308
14.4 ASIA PACIFIC 313
14.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 318
14.4.2 CHINA 319
14.4.2.1 China to dominate Asia Pacific market during forecast period 319
14.4.3 JAPAN 323
14.4.3.1 Rising number of collaborations in genomics to drive market 323
14.4.4 INDIA 327
14.4.4.1 Government and private initiatives for genomics to propel market 327
14.4.5 AUSTRALIA 331
14.4.5.1 Increased genomics research in Australia to support market growth 331
14.4.6 SOUTH KOREA 335
14.4.6.1 Demand for advanced sequencing technologies to support market growth in South Korea 335
14.4.7 REST OF ASIA PACIFIC 339
14.5 LATIN AMERICA 345
14.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 349
14.5.2 BRAZIL 350
14.5.2.1 Increased government investments in genomics advancements to drive market in Brazil 350
14.5.3 MEXICO 354
14.5.3.1 Rising demand for chronic disease treatment to support market growth in Mexico 354
14.5.4 REST OF LATIN AMERICA 358
14.6 MIDDLE EAST 363
14.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK 366
14.6.2 GCC COUNTRIES 367
14.6.2.1 Saudi Arabia 371
14.6.2.1.1 Growing healthcare expenditure in Saudi Arabia to boost market growth 371
14.6.2.2 United Arab Emirates 376
14.6.2.2.1 Growing collaborations to advance genome sequencing to aid market growth in UAE 376
14.6.2.3 Rest of GCC Countries 380
14.6.3 REST OF MIDDLE EAST 385
14.7 AFRICA 389
14.7.1 GROWING FOCUS ON PRECISION MEDICINE TO PROPEL MARKET IN AFRICA 389
14.7.2 AFRICA: MACROECONOMIC OUTLOOK 393
15 COMPETITIVE LANDSCAPE 395
15.1 INTRODUCTION 395
15.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 395
15.3 REVENUE ANALYSIS 397
15.4 MARKET SHARE ANALYSIS 398
15.5 BRAND/PRODUCT COMPARATIVE ANALYSIS 400
15.5.1 ILLUMINA, INC. 401
15.5.2 THERMO FISHER SCIENTIFIC INC. 401
15.5.3 DANAHER CORPORATION 401
15.5.4 ROCHE 401
15.5.5 QIAGEN 401
15.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 401
15.6.1 STARS 402
15.6.2 EMERGING LEADERS 402
15.6.3 PERVASIVE PLAYERS 402
15.6.4 PARTICIPANTS 402
15.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 404
15.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 409
15.7.1 PROGRESSIVE COMPANIES 409
15.7.2 RESPONSIVE COMPANIES 409
15.7.3 DYNAMIC COMPANIES 409
15.7.4 STARTING BLOCKS 409
15.7.5 COMPETITIVE BENCHMARKING 411
15.8 VALUATION AND FINANCIAL METRICS OF GENOMICS VENDORS 412
15.9 COMPETITIVE SCENARIO 413
15.9.1 DEALS 413
15.9.2 EXPANSIONS 414
16 COMPANY PROFILES 415
16.1 KEY PLAYERS 415
16.1.1 ILLUMINA, INC. 415
16.1.1.1 Business overview 415
16.1.1.2 Products/Services offered 416
16.1.1.3 Recent developments 419
16.1.1.3.1 Product launches 419
16.1.1.3.2 Deals 421
16.1.1.3.3 Expansions 423
16.1.1.4 MnM view 424
16.1.1.4.1 Key strengths 424
16.1.1.4.2 Strategic choices 424
16.1.1.4.3 Weaknesses and competitive threats 424
16.1.2 THERMO FISHER SCIENTIFIC INC. 425
16.1.2.1 Business overview 425
16.1.2.2 Products/Services offered 426
16.1.2.3 Recent developments 431
16.1.2.3.1 Product launches 431
16.1.2.3.2 Deals 434
16.1.2.3.3 Expansions 435
16.1.2.4 MnM view 436
16.1.2.4.1 Key strengths 436
16.1.2.4.2 Strategic choices 436
16.1.2.4.3 Weaknesses and competitive threats 436
16.1.3 F. HOFFMANN-LA ROCHE LTD. 437
16.1.3.1 Business overview 437
16.1.3.2 Products/Services offered 438
16.1.3.2.1 Product launches 440
16.1.3.2.2 Deals 442
16.1.3.3 MnM view 442
16.1.3.3.1 Key strengths 442
16.1.3.3.2 Strategic choices 442
16.1.3.3.3 Weaknesses and competitive threats 442
16.1.4 DANAHER CORPORATION 443
16.1.4.1 Business overview 443
16.1.4.2 Products/Services offered 444
16.1.4.2.1 Product launches 446
16.1.4.2.2 Deals 448
16.1.4.2.3 Expansions 449
16.1.5 QIAGEN 450
16.1.5.1 Business overview 450
16.1.5.2 Products/Services offered 451
16.1.5.3 Recent developments 454
16.1.5.3.1 Deals 456
16.1.5.3.2 Expansions 457
16.1.6 AGILENT TECHNOLOGIES, INC. 458
16.1.6.1 Business overview 458
16.1.6.2 Products/Services offered 459
16.1.6.3 Recent developments 462
16.1.6.3.1 Deals 463
16.1.6.3.2 Expansions 464
16.1.7 REVVITY 465
16.1.7.1 Business overview 465
16.1.7.2 Products/Services offered 466
16.1.7.3 Recent developments 469
16.1.7.3.1 Product launches 469
16.1.7.3.2 Deals 470
16.1.7.3.3 Expansions 470
16.1.8 LABORATORY CORPORATION OF AMERICA HOLDINGS 471
16.1.8.1 Business overview 471
16.1.8.2 Services offered 472
16.1.8.3 Recent developments 473
16.1.8.3.1 Service launches 473
16.1.8.3.2 Deals 474
16.1.9 IQVIA INC. 475
16.1.9.1 Business overview 475
16.1.9.2 Services offered 476
16.1.9.3 Recent developments 477
16.1.9.3.1 Deals 477
16.1.9.3.2 Expansions 477
16.1.10 CHARLES RIVER LABORATORIES 479
16.1.10.1 Business overview 479
16.1.10.2 Services offered 480
16.1.10.3 Recent developments 481
16.1.10.3.1 Deals 481
16.1.11 BIO-RAD LABORATORIES, INC. 482
16.1.11.1 Business overview 482
16.1.11.2 Products/Services offered 483
16.1.11.3 Recent developments 485
16.1.11.3.1 Product launches 485
16.1.11.3.2 Deals 486
16.1.12 EUROFINS SCIENTIFIC 487
16.1.12.1 Business overview 487
16.1.12.2 Products/Services offered 488
16.1.12.3 Recent developments 489
16.1.12.3.1 Product launches 489
16.1.12.3.2 Deals 490
16.1.13 PACBIO 491
16.1.13.1 Business overview 491
16.1.13.2 Products/Services offered 492
16.1.13.3 Recent developments 495
16.1.13.3.1 Product & service launches 495
16.1.13.3.2 Deals 496
16.1.13.3.3 Expansions 497
16.1.13.3.4 Other developments 497
16.1.14 OXFORD NANOPORE TECHNOLOGIES PLC. 498
16.1.14.1 Business overview 498
16.1.14.2 Products/Services offered 499
16.1.14.3 Recent developments 501
16.1.14.3.1 Product & service launches 501
16.1.14.3.2 Deals 501
16.1.15 TAKARA BIO INC. 504
16.1.15.1 Business overview 504
16.1.15.2 Products/Services offered 505
16.1.15.3 Recent developments 509
16.1.15.3.1 Product & service launches 509
16.1.15.3.2 Deals 509
16.1.16 BGI GROUP 510
16.1.16.1 Business overview 510
16.1.16.2 Products/Services offered 510
16.1.16.3 Recent developments 514
16.1.16.3.1 Product & service launches 514
16.1.16.3.2 Deals 516
16.1.16.3.3 Other developments 516
16.1.17 EPPENDORF SE 517
16.1.17.1 Business overview 517
16.1.17.2 Products/Services offered 518
16.1.17.3 Recent developments 519
16.1.17.3.1 Product & service launches 519
16.1.18 MERCK KGAA 520
16.1.18.1 Business overview 520
16.1.18.2 Products/Services offered 521
16.1.18.3 Recent developments 523
16.1.18.3.1 Expansions 523
16.1.19 BD 524
16.1.19.1 Business overview 524
16.1.19.2 Products/Services offered 525
16.1.19.3 Recent developments 527
16.1.19.3.1 Product & service launches 527
16.1.19.3.2 Deals 529
16.1.20 ABBOTT 530
16.1.20.1 Business overview 530
16.1.20.2 Products/Services offered 531
16.1.20.3 Recent developments 534
16.1.20.3.1 Product & service launches 534
16.1.21 10X GENOMICS 535
16.1.21.1 Business overview 535
16.1.21.2 Products/Services offered 536
16.1.21.3 Recent developments 538
16.1.21.3.1 Product launches 538
16.1.22 NEW ENGLAND BIOLABS 539
16.1.22.1 Business overview 539
16.1.22.2 Products/Services offered 539
16.1.22.3 Recent developments 542
16.1.22.3.1 Product & service launches 542
16.1.22.3.2 Deals 543
16.1.23 PROMEGA CORPORATION 544
16.1.23.1 Business overview 544
16.1.23.2 Products/Services offered 544
16.1.23.3 Recent developments 546
16.1.23.3.1 Product & service launches 546
16.1.23.3.2 Other developments 546
16.2 OTHER PLAYERS 547
16.2.1 CREATIVE BIOGENE 547
16.2.2 NOVOGENE CO., LTD. 549
16.2.3 HELIX, INC. 550
16.2.4 PHALANX BIOTECH GROUP 551
16.2.5 POLARIS GENOMICS 552
17 APPENDIX 553
17.1 DISCUSSION GUIDE 553
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 558
17.3 CUSTOMIZATION OPTIONS 560
17.4 RELATED REPORTS 561
17.5 AUTHOR DETAILS 562
❖ 世界のゲノミクス市場に関するよくある質問(FAQ) ❖
・ゲノミクスの世界市場規模は？
→MarketsandMarkets社は2024年のゲノミクスの世界市場規模を426.4億米ドルと推定しています。
・ゲノミクスの世界市場予測は？
→MarketsandMarkets社は2029年のゲノミクスの世界市場規模を668.5億米ドルと予測しています。
・ゲノミクス市場の成長率は？
→MarketsandMarkets社はゲノミクスの世界市場が2024年～2029年に年平均9.4%成長すると予測しています。
・世界のゲノミクス市場における主要企業は？
→MarketsandMarkets社は「Illumina、Inc. (US)、Thermo Fisher Scientific Inc. (US)、F. Hoffmann-LA Roche Ltd. (Switzerland)、Danaher Corporation (US)、QIAGEN (Germany)、Agilent Technologies、Inc. (US)、Revvity (US)、Laboratory Corporation of America Holdings (US)、IQVIA Inc. (US)、Charles River Laboratories (US)、Bio-Rad Laboratories、Inc. (US)、Eurofins Scientific (Luxembourg)、PacBio (US)、Oxford Nanopore Technologies plc. (UK)、Takara Bio Inc. (Japan)、BGI Group (China)、Eppendorf SE (Germany)、Merck KGaA (Germany)、BD (US)、Abbott (US)、10X Genomics (US)、New England Biolabs (US)、Promega Corporation (US)、Creative Biogene (US)、Novogene Co.、Ltd. (China)、Helix、Inc. (US)、Phalanx Biotech Group (US)、Polaris Genomics (US)など ...」をグローバルゲノミクス市場の主要企業として認識しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。
